Skip to main content
      RT @RichardPAConway: HAS-GCA study @alwinuk @profbdasgupta Southend pretest probability score and Halo score useful in d

      Richard Conway RichardPAConway

      2 years 5 months ago
      HAS-GCA study @alwinuk @profbdasgupta Southend pretest probability score and Halo score useful in diagnosis and prognosis in GCA. Halo score may be useful for monitoring. @RheumNow #EULAR2022 POS0818 https://t.co/sxYjnQQFA8
      RT @AurelieRheumo: Do you vaccine pts w/ RMDs for shingles?
      If so, when and who and with what?
      @khyrich highlights diffe

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      Do you vaccine pts w/ RMDs for shingles? If so, when and who and with what? @khyrich highlights differences in recommendations and contra-indications across countries #EULAR2022 @RheumNow https://t.co/c0uvOPopF4
      RT @KDAO2011: “One of the benefits of #vaccinations people don’t talk about is the relief they feel after vaccinatio

      TheDaoIndex KDAO2011

      2 years 5 months ago
      “One of the benefits of #vaccinations people don’t talk about is the relief they feel after vaccination." - Dr E Hyrich #EULAR2022 @rheumnow
      RheumNow’s coverage of the #EULAR2022 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chos

      Dr. John Cush RheumNow

      2 years 5 months ago
      RheumNow’s coverage of the #EULAR2022 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.
      RT @AurelieRheumo: 💫Trajectory analysis in SpA💫

      Data on 1,125 patients
      Prediction of spinal radiographic progress

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      💫Trajectory analysis in SpA💫 Data on 1,125 patients Prediction of spinal radiographic progression ⭐️FAST associated w/ onset at older age & 👁involvement ⭐️SLOW progression associated w/ female gender & peripheral involvement. #EULAR2022 @RheumNow OP0151 https://t.co/E80qCLEtBv
      RT @RichardPAConway: Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing comp

      Richard Conway RichardPAConway

      2 years 5 months ago
      Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing complete clinical response but only 20% complete imaging response at month 12. Clinical implications of these persistent imaging findings need clarification @RheumNow #EULAR2022 POS0804 https://t.co/sNbRzIkwnt
      RT @ericdeinmd: #EULAR2022
      "The mRNA vaccines are simple to make." - Saul Faust
      The key step is encapsulation in lipid

      Eric Dein ericdeinmd

      2 years 5 months ago
      #EULAR2022 "The mRNA vaccines are simple to make." - Saul Faust The key step is encapsulation in lipid to allow for take up by cell. 💉💉💉 @RheumNow https://t.co/T2ZxF6bLV5
      RT @RichardPAConway: Comorbidity in AS from @rheum_cat , Karmacharya et al. Clustering of comorbidities. Depression and

      Richard Conway RichardPAConway

      2 years 5 months ago
      Comorbidity in AS from @rheum_cat , Karmacharya et al. Clustering of comorbidities. Depression and hypertension clusters assoc worse disease activity and function @RheumNow #EULAR2022 OP0154 https://t.co/jGQXayAYs9 https://t.co/SnVDhVYQq5
      RT @RichardPAConway: Flatman et al. Serious infections in babies born to women using TNFi during pregnancy. 2902 babies.

      Richard Conway RichardPAConway

      2 years 5 months ago
      Flatman et al. Serious infections in babies born to women using TNFi during pregnancy. 2902 babies. Adjusted HR 1.20 (0.54-2.64) for agents with high vs low placental transfer. @RheumNow #EULAR2022 OP0130 https://t.co/oaW7wDPxva
      RT @ericdeinmd: #EULAR2022 OP0134: Active RA increases risk of dementia

      Olmsted County, MINN studying RA risk factors f

      Eric Dein ericdeinmd

      2 years 5 months ago
      #EULAR2022 OP0134: Active RA increases risk of dementia Olmsted County, MINN studying RA risk factors for dementia: ⭐️886 pts incident RA, mean age 65. 103 develop dementia Risk factors: Age, rheum nodules, large jt swelling, depression/anxiety, HTN, CVD events @Rheumnow https://t.co/bUFkzBovAy
      RT @RichardPAConway: Fonzetti et al. Isolated Ro-52 in pSS. 300 patients. Less inflammatory features but more fibrotic d

      Richard Conway RichardPAConway

      2 years 5 months ago
      Fonzetti et al. Isolated Ro-52 in pSS. 300 patients. Less inflammatory features but more fibrotic disease - ILD and PBC. @RheumNow #EULAR2022 OP0146 https://t.co/2WIAu8qKiH https://t.co/mspSBNxbx2
      RT @KDAO2011: Prof T Dorner summarizes what's new in #SLE #EULAR2022
      @rheumnow https://t.co/YT0Ocw7I41

      TheDaoIndex KDAO2011

      2 years 5 months ago
      Prof T Dorner summarizes what's new in #SLE #EULAR2022 @rheumnow https://t.co/YT0Ocw7I41
      RT @RichardPAConway: Large collaborative study on IIM treatment patterns from @Nellziade @ElenaNikiUK @LatikaGupta_ @drh

      Richard Conway RichardPAConway

      2 years 5 months ago
      Large collaborative study on IIM treatment patterns from @Nellziade @ElenaNikiUK @LatikaGupta_ @drhectorchinoy @MarcinMilchert and many others. Significant geographic differences, highlighting need for consensus guidelines @RheumNow #EULAR2022 OP0161 https://t.co/osaORtgvxh https://t.co/96PypMtlcl
      RT @ericdeinmd: #EULAR2022 OP0138:
      BIOBADASER registry:
      Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior

      Eric Dein ericdeinmd

      2 years 5 months ago
      #EULAR2022 OP0138: BIOBADASER registry: Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior malignancy ⭐️352 pts w prior malignancy in registry, 32 developed a 2nd incident malignancy 27 rate of cancer/1000 patient years. No diff of cancer or mortality b/w Rx @Rheumnow https://t.co/nTuUooBmzV
      RT @RichardPAConway: Ghalandari et al EUDRAVIGILANCE database congenital malformations for non-TNFi bDMARDs (vs certoliz

      Richard Conway RichardPAConway

      2 years 5 months ago
      Ghalandari et al EUDRAVIGILANCE database congenital malformations for non-TNFi bDMARDs (vs certolizumab). ORs suggest possible B-cell modulators and vedolizumab, not others. Geneticist rvw no pattern for B-cell agents. @RheumNow #EULAR2022 OP0129 https://t.co/nrj8MxjAri https://t.co/p6JkfjjtdH